Technical Analysis for GILD - Gilead Sciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
66.17 | 0.44% | 0.29 |
GILD closed up 0.44 percent on Tuesday, September 17, 2019, on 84 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Flat |
| See historical GILD trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Hammer Candlestick | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.44% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.44% | |
| NR7 | Range Contraction | 0.44% | |
| Overbought Stochastic | Strength | 0.44% | |
| 200 DMA Support | Bullish | -1.09% | |
| Upper Bollinger Band Walk | Strength | -1.09% | |
| Overbought Stochastic | Strength | -1.09% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/23/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis Cardiovascular Diseases HIV Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases AIDS Gilead Sciences Prodrugs Cytomegalovirus Retinitis Fungal Infections Liver Disease Tenofovir Disoproxil
Medicine Chemistry Biopharmaceutical Diseases Infection Organic Chemistry Cystic Fibrosis Cardiovascular Diseases HIV Pulmonary Arterial Hypertension Hepatotoxins Respiratory Diseases AIDS Gilead Sciences Prodrugs Cytomegalovirus Retinitis Fungal Infections Liver Disease Tenofovir Disoproxil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GILD news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 79.61 |
| 52 Week Low | 60.32 |
| Average Volume | 5,749,475 |
| 200-Day Moving Average | 65.9402 |
| 50-Day Moving Average | 65.1902 |
| 20-Day Moving Average | 64.639 |
| 10-Day Moving Average | 65.853 |
| Average True Range | 1.3551 |
| ADX | 19.61 |
| +DI | 23.1154 |
| -DI | 18.8415 |
| Chandelier Exit (Long, 3 ATRs ) | 64.0947 |
| Chandelier Exit (Short, 3 ATRs ) | 66.2553 |
| Upper Bollinger Band | 67.9056 |
| Lower Bollinger Band | 61.3724 |
| Percent B (%b) | 0.73 |
| BandWidth | 10.107211 |
| MACD Line | 0.5289 |
| MACD Signal Line | 0.2059 |
| MACD Histogram | 0.323 |
| Fundamentals | Value |
|---|---|
| Market Cap | 86.42 Billion |
| Num Shares | 1.31 Billion |
| EPS | 9.21 |
| Price-to-Earnings (P/E) Ratio | 7.18 |
| Price-to-Sales | 3.57 |
| Price-to-Book | 4.49 |
| PEG Ratio | -1.08 |
| Dividend | 2.08 |
| Dividend Yield | 3.14% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 67.61 | ||||
| Resistance 3 (R3) | 67.47 | 66.86 | 67.37 | ||
| Resistance 2 (R2) | 66.86 | 66.49 | 66.93 | 67.29 | |
| Resistance 1 (R1) | 66.51 | 66.26 | 66.69 | 66.65 | 67.21 |
| Pivot Point | 65.90 | 65.90 | 65.98 | 65.97 | 65.90 |
| Support 1 (S1) | 65.55 | 65.53 | 65.73 | 65.69 | 65.13 |
| Support 2 (S2) | 64.94 | 65.30 | 65.01 | 65.05 | |
| Support 3 (S3) | 64.59 | 64.94 | 64.97 | ||
| Support 4 (S4) | 64.73 |
